Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Immunomodulatory Effects of Drugs for Cancer Immunotherapy
share announcement

Immunomodulatory Effects of Drugs for Cancer Immunotherapy

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biologics and Biosimilars".

Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 3844

Special Issue Editors

Dr. Maiko Matsushita

E-Mail Website
Guest Editor
Division of Clinical Physiology and Therapeutics Keio University Faculty of Pharmacy 1-5-30, Shiba-koen, Minato-ku, Tokyo 105-8512, Japan
Interests: cancer immunotherapy; drug repositioning; multiple myeloma; prostate cancer
Dr. Takeshi Suzuki

E-Mail Website
Guest Editor
Division of Basic Biological Science, Faculty of Pharmacy, Keio University, Tokyo 105-8512, Japan
Interests: neuroscience; drug development

Special Issue Information

Dear Colleagues,

Recent advances in cancer immunotherapy, including those in immune checkpoint inhibitors (ICIs) or adoptive T-cell therapies, have contributed to better outcomes in cancer patients. However, even ICIs are ineffective in the treatment of certain cancers. Therefore, new strategies to enhance the efficacy of treatments are needed. It has been reported that several commonly used drugs, such as statin, exert immune-modulatory effects; due to such properties, these drugs are expected to enhance the body’s immunity against cancer cells.

This Special Issue aims to further develop the current body of literature on the current knowledge regarding the immunomodulatory effects of a wide variety of drugs, which will aid the advancement and development of cancer therapy.

We are inviting submissions of review or original articles on all aspects of “Immunomodulatory Effects of Drugs for Cancer Immunotherapy”.

Dr. Maiko Matsushita
Dr. Takeshi Suzuki
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • immunomodulatory
  • immunostimulatory
  • drug
  • drug repositioning
  • chemotherapeutic agents.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

29 pages, 1425 KiB  
Review
Induced Vascular Normalization—Can One Force Tumors to Surrender to a Better Microenvironment?
by Xu Xin Sun, Zeynab Nosrati, Janell Ko, Che-Min Lee, Kevin L. Bennewith and Marcel B. Bally
Pharmaceutics 2023, 15(8), 2022; https://doi.org/10.3390/pharmaceutics15082022 - 26 Jul 2023
Viewed by 1803
Abstract
Immunotherapy has changed the way many cancers are being treated. Researchers in the field of immunotherapy and tumor immunology are investigating similar questions: How can the positive benefits achieved with immunotherapies be enhanced? Can this be achieved through combinations with other agents and [...] Read more.
Immunotherapy has changed the way many cancers are being treated. Researchers in the field of immunotherapy and tumor immunology are investigating similar questions: How can the positive benefits achieved with immunotherapies be enhanced? Can this be achieved through combinations with other agents and if so, which ones? In our view, there is an urgent need to improve immunotherapy to make further gains in the overall survival for those patients that should benefit from immunotherapy. While numerous different approaches are being considered, our team believes that drug delivery methods along with appropriately selected small-molecule drugs and drug candidates could help reach the goal of doubling the overall survival rate that is seen in some patients that are given immunotherapeutics. This review article is prepared to address how immunotherapies should be combined with a second treatment using an approach that could realize therapeutic gains 10 years from now. For context, an overview of immunotherapy and cancer angiogenesis is provided. The major targets in angiogenesis that have modulatory effects on the tumor microenvironment and immune cells are highlighted. A combination approach that, for us, has the greatest potential for success involves treatments that will normalize the tumor’s blood vessel structure and alter the immune microenvironment to support the action of immunotherapeutics. So, this is reviewed as well. Our focus is to provide an insight into some strategies that will engender vascular normalization that may be better than previously described approaches. The potential for drug delivery systems to promote tumor blood vessel normalization is considered. Full article
(This article belongs to the Special Issue Immunomodulatory Effects of Drugs for Cancer Immunotherapy)
►▼ Show Figures

Figure 1

26 pages, 2028 KiB  
Review
Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?
by Elise Timon-David, Carla Perez and Anne Rodallec
Pharmaceutics 2022, 14(11), 2326; https://doi.org/10.3390/pharmaceutics14112326 - 28 Oct 2022
Cited by 2 | Viewed by 1526
Abstract
While the number of oncology-related nanotherapeutics and immunotherapies is constantly increasing, cancer patients still suffer from a lack of efficacy and treatment resistance. Among the investigated strategies, patient selection and combinations appear to be of great hope. This review will focus on combining [...] Read more.
While the number of oncology-related nanotherapeutics and immunotherapies is constantly increasing, cancer patients still suffer from a lack of efficacy and treatment resistance. Among the investigated strategies, patient selection and combinations appear to be of great hope. This review will focus on combining nanotherapeutics and immunotherapies together, how they can dually optimize each other to face such limits, bringing us into a new field called nano-immunotherapy. While looking at current clinical trials, we will expose how passive immunotherapies, such as antibodies and ADCs, can boost nanoparticle tumor uptake and tumor cell internalization. Conversely, we will study how immunotherapies can benefit from nanotherapeutics which can optimize their lipophilicity, permeability, and distribution (e.g., greater tumor uptake, BBB crossing, etc.), tumor, tumor microenvironment, and immune system targeting properties. Full article
(This article belongs to the Special Issue Immunomodulatory Effects of Drugs for Cancer Immunotherapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop